In addition, PD-L1 CAR-NK cells in combination with the anti-PD-1 blockade antibody Nivolumab showed a synergistic anti-tumor response in a humanized mouse nasopharyngeal carcinoma patient-derived xenograft model [178]. The gene discussed is PDCD1; the disease is neoplasm.